Ex-PRESS R-50 miniature glaucoma implant insertion under the conjunctiva combined with cataract extraction

THESE
préparée sous la direction du
Professeur associé André Mermoud
et présentée à la Faculté de biologie et de médecine de
l'Université de Lausanne pour l'obtention
du grade de
DOCTEUR EN MEDECINE
par

Delphine RIVIER

Médecin diplômée de la Confédération Suisse
Originaire de Lausanne (VD), Aubonne (VD) et Genève (GE)

Lausanne
2008
Rapport de synthèse

Le glaucome à angle ouvert est une neuropathie optique chronique progressive pour laquelle de nombreux traitements tant médicaux que chirurgicaux ont été proposés. La prise en charge chirurgicale s’articule principalement autour de deux chirurgies filtrantes, la trabéculectomie et la sclérectomie profonde avec implant de collagène. Cependant, les complications postopératoires de ces deux interventions étant relativement fréquentes, la recherche s’est orientée vers des traitements alternatifs dont la mise en place de micro-drains. Ces implants de drainage diminuent la pression intraoculaire en créant un court-circuit du flux d’humeur aqueuse de la chambre antérieure vers l’espace sous-conjonctival avec formation d’une bulle de filtration. L’implant Ex-PRESS R-50 est un implant miniature (2,5 mm de long pour 400 µm de diamètre) en acier inoxydable et biocompatible.

La présente étude s’est proposée d’étudier l’efficacité et la sécurité de l’implant miniature Ex-Press R-50 lors d’une opération combinée cataracte-glaucome. Trente-cinq yeux de 35 patients (âge moyen: 75 ans) ont été inclus dans l’étude. Tous les patients ont bénéficié d’une opération de la cataracte par phacoémulsification et mise en place d’un implant de chambre postérieure suivie de l’implantation du micro-drain. Les pressions intraoculaires préopératoires et postopératoires, la meilleure acuité visuelle corrigée, le nombre de médicaments anti-glaucomateux ainsi que le type et le nombre de complications ont été évalués mensuellement puis tous les 6 mois pendant 4 ans. Le succès total a été défini par une pression postopératoire finale inférieure à 18mmHg sans traitement médical associé, le succès partiel par une pression postopératoire finale inférieure à 18mmHg avec ou sans traitement médical associé.

Le suivi moyen a été de 36.9 mois avec une baisse de la pression intraoculaire significative d’environ 25%. Une augmentation de l’acuité visuelle a été observée après l’opération de la cataracte et le nombre de médicaments anti-glaucomateux a été réduit de 57%. Dix patients ont bénéficié d’un traitement supplémentaire de la bulle de filtration par injection d’anti-métabolite (mitomycine C). Nous avons observé 8 complications majeures (4 érosions conjonctivales et 4 obstructions de l’orifice interne du micro-drain), toutes suivies de l’ablation de l’implant et de la réalisation d’une chirurgie classique du glaucome. En se basant sur les courbes de Kaplan-Meier à 48 mois, le taux de succès total était de 32.7% et le succès partiel de 53.7%.

Nous pouvons conclure suite à ce travail que l’implant miniature Ex-PRESS R-50 est associé à un nombre trop élevé de complications, même si les cas non compliqués ont bénéficié d’une baisse significative de la pression intraoculaire. La modification de l’architecture du micro-drain ainsi que de la technique chirurgicale devrait augmenter le taux de succès.
Ex-PRESS R-50 miniature glaucoma implant insertion under the conjunctiva combined with cataract extraction

Delphine Rivier, MD, Sylvain Roy, MD, MSc, André Mermoud, MD

PURPOSE: To evaluate the efficacy and safety of the Ex-PRESS R-50 implant (Optonol Ltd.) in eyes operated on for open-angle glaucoma combined with phacoemulsification.

SETTING: Glaucoma Unit, Ophthalmology Department, University of Lausanne, Lausanne, Switzerland.

METHODS: Between November 2000 and June 2002, the Ex-PRESS R-50 shunt was implanted in 35 eyes of 35 patients. The best corrected visual acuity (BCVA), intraocular pressure (IOP), number of medications, and complications were recorded preoperatively as well as postoperatively at 1 and 7 days and 1, 2, 3, 6, 9, 12, 24, 36, and 48 months. Temporal clear corneal phacoemulsification with intraocular lens implantation was performed first. The ophthalmic viscosurgical device was not removed, and the Ex-PRESS R-50 was implanted under the conjunctiva into the anterior chamber.

RESULTS: The mean follow-up was 36.9 months ± 18.2 (SD) and the mean age of the patients, 74.6 ± 10.9 years. The mean preoperative IOP of 19.3 ± 6.3 mm Hg decreased postoperatively to 15.3 ± 6.2 mm Hg, 15.1 ± 4.6 mm Hg, 13.8 ± 2.8 mm Hg, 14.6 ± 2.9 mm Hg, and 13.3 ± 2.0 mm Hg at 6 months, 12 months, 24 months, 36 months, and 48 months, respectively (P<.005). At 48 months, the mean BCVA was 0.74 ± 0.34 and the number of medications was reduced by 57% (P<.005). The microtube was removed in 10 patients, and bleb management was performed in 10 eyes. Ten patients (32%) had satisfactory IOP control (mean 13.2 ± 2.2 mm Hg) without medication; minor transient complications were observed in 1 patient. Based on the cumulative survival curve after 48 months, the complete success rate was 32.7% and the qualified success rate, 53.7% (P<.05).

CONCLUSIONS: Ex-PRESS R-50 implantation under the conjunctiva was associated with a relatively high number of complications, despite good IOP control in the uncomplicated cases. Refinement in the tube design and implantation technique would increase the success rate.


Deep sclerectomy with collagen implant surgery was initially designed to lower the complication rates encountered with the most commonly used penetrating procedure, trabeculectomy. Complications included hyphema, anterior chamber inflammation, excessive filtration leading to hypotony, a flat anterior chamber, surgery-induced cataract, choroidal detachment, hypotony-related maculopathy, and endophthalmitis. Because deep sclerectomy is a nonpenetrating procedure, most complications were avoided or significantly reduced. Despite these advantages, the technique has drawbacks, such as a relatively long learning curve and a delicate surgical technique, that explain the relatively high rate of conversion from deep sclerectomy to trabeculectomy during surgery.

To alleviate the complications, the search for alternative treatments to conventional glaucoma filtering surgery has intensified and penetrating filtering surgery using miniature glaucoma drainage devices has gained renewed interest since the introduction of large drainage devices almost a century ago. These devices create alternative aqueous pathways by draining aqueous from the anterior chamber through a long tube to an equatorial plate that promotes bleb formation. They have been commonly used in refractory glaucoma when other modes of treatment, nonsurgical and surgical, have failed. Results in such cases of complicated glaucoma were difficult to analyze, and no definitive conclusions could be drawn from these studies. However, experience in the use of such
devices led to several modifications in their design and construction and in the techniques for their implantation. The first miniature glaucoma implant, the Ex-PRESS R-50 (Optonol Ltd.), was developed in 1998. The implant is a nonvalved device that is implanted at the limbus to drain aqueous humor from the anterior chamber to the subconjunctival space, creating a conjunctival filtration bleb, similar to trabeculectomy. Several articles on the Ex-PRESS R-50 implant have been published. Five studies of 26, 24, 16, 50, and 99 eyes, respectively, found encouraging results with a safe and efficient procedure. Two case series with 11 and 4 eyes, respectively, and 1 case report concluded that the complication rate was unacceptably high, in particular with respect to the risk for endophthalmitis after conjunctival erosion. The purpose of this study was to evaluate the efficacy and safety of the Ex-PRESS R-50 miniature glaucoma implant placed under the conjunctiva in reducing intraocular pressure (IOP) in eyes operated on for open-angle glaucoma combined with phacoemulsification and posterior chamber intraocular lens (PC IOL) implantation.

PATIENTS AND METHODS

In this nonrandomized nonmasked prospective trial, the Ex-PRESS R-50 microtube was implanted in 35 eyes of 35 patients at the Glaucoma Unit, Ophthalmology Department, University of Lausanne, between November 2000 and June 2002. The patients, nonconsecutive cases, were enrolled in this study after formal approval by the Ethical Committee of the University of Lausanne. Preference for this technique over other filtering surgery was based on the patient’s willingness to participate in the study. Each patient received a comprehensive explanation of the study and its implications and signed a written informed consent before surgery.

Patients eligible for the study were older than 18 years. All had medically uncontrolled primary open-angle glaucoma (POAG) or pseudoxfoliative glaucoma (PXFG) associated with cataract. Uncontrolled glaucoma was defined as elevated IOP, a progression of optic nerve cupping, and/or deterioration of the visual field as assessed by an experienced glaucoma specialist. Patients who had side effects from antiglaucoma medication and eyes that required good IOP control without medication were also included. All eyes were under maximum tolerated medical therapy (2 or more antiglaucoma medications), had previous filtering surgery that failed, or both. In eyes with a previous failed filtering surgery, the quadrant used to implant the Ex-PRESS R-50 microtube was different from that in the initial surgery. This approach was used to minimize interference with possible conjunctival scarring or remodeling reaction from the former surgery. The mean decrease in preoperative best corrected visual acuity (BCVA) was mainly due to cataract development. The lens opacities estimation was made by slitlamp examination, and this assessment was used for the indication of a combined procedure when glaucoma surgery was concomitantly required. Cataract extraction was proposed when the mean preoperative BCVA was worse than 0.7 or the patient reported disturbing glare in the presence of lens opacities.

Eyes with angle-closure glaucoma, normal-tension glaucoma, neovascular glaucoma, or congenital or juvenile glaucoma were excluded from the study. Filtering surgery performed less than 1 year before enrollment in this study and a monocular status were also criteria for exclusion. The primary outcome measure was the IOP. The secondary outcome measures were BCVA, use of antiglaucoma medications, and type and number of perioperative or postoperative complications. Based on the cup-to-disc ratio, the severity of glaucoma was classified into 3 groups: early (0.30 to 0.59), moderate (0.60 to 0.79), and severe (0.80 to 1.00).

Data Recorded Preoperatively

On enrollment, all patients had a comprehensive ophthalmic examination that included measurement of the distance BCVA using Snellen charts at 6 m, anterior segment slitlamp biomicroscopy, fundus evaluation, a single-reading IOP measurement with a Goldmann applanation tonometer (without diurnal fluctuation taken into account), and automated visual field evaluation (Octopus 101, Haag-Streit) within 6 months before enrollment.

Glaucoma Drainage Implant

The Ex-PRESS R-50 implant is a miniature glaucoma drainage device made of biocompatible stainless steel. The tube is 2.50 mm in overall length, with 2.00 mm being intracocular. The external diameter is approximately 400 μm (27 gauge) and the inner bore, 50 μm. A detailed description of the Ex-PRESS R-50 technique has been published.

Surgical Technique

All operations were performed by the same experienced ophthalmic surgeon (A.M.) using retrobulbar anesthesia consisting of 2 to 4 mL of a bupivacaine 0.75%, lidocaine hydrochloride 4%, and 50 IU hyaluronidase mixed solution.
A retrobulbar procedure was preferred to peribulbar to prevent an increase in IOP during injection of the solution. Temporal sutureless clear corneal phacoemulsification cataract extraction with in-the-bag acrylic hydrophilic foldable intraocular lens (IOL) implantation was performed first through a 3.5 mm incision; the ophthalmic viscosurgical device (OVD) was left in the anterior chamber. For implantation of the Ex-PRESS R-50 device, a 2.0 to 4.0 mm circumferential conjunctival opening was created 10.0 to 15.0 mm posterior to the limbus. The device, mounted on its introducer, was slid under the conjunctiva and Tenon's capsule into the anterior chamber and implanted radial to the limbus and parallel to the iris through a precission made with a 27-gauge needle 2.0 mm from the limbus. The introducer was then withdrawn and the conjunctiva closed with an 8-0 polyglactin (Vicryl) running suture. No patch, such as Tutoplast or a graft, was used to cover the implant. The time required to implant the device was approximately 3 minutes. Postoperative treatment consisted of topical application of tobramycin and dexamethasone 5 times a day followed by gradual tapering over approximately 4 weeks.

**Success Criteria**

Surgery was considered a complete success when the IOP was 18 mm Hg or less and 6 mm Hg or more without medication. The same criteria with or without medication were used to define qualified success. Surgery was considered a failure when IOP was higher than 18 mm Hg despite medication and/or further glaucoma surgery was required or the implant explanted. Patients having removal of the implant, and thus considered failed cases, were not included in the subsequent postoperative follow-ups. Postoperative complications were considered minor if they resolved spontaneously or required minimal surgical revision. The major complications required removal of the device and further filtering surgery.

**Postoperative Follow-up**

The BCVA, IOP, number of medications, and complications were recorded preoperatively as well as 1 and 7 days and 1, 2, 3, 6, 9, 12, 24, 36, and 48 months after surgery. Follow-up was more frequent when required by the clinical situation.

Any complication was recorded and was defined as major or minor based on the clinical significance and importance over time. Evaluation of the complications was based on the surgeon's clinical experience. Cases of cornea-device contact and iris-device contact were assessed under slitlamp examination. Hyphema was considered present when blood collection was seen in the anterior chamber. Anterior chamber depth was clinically assessed under slitlamp examination and was considered shallow when iridocorneal touch in the periphery was noticed. Chloroidal detachment was observed under indirect ophthalmoscopy. Complications were considered minor if they resolved spontaneously or required minimal surgical revision. The major complications required removal of the device and further filtering surgery.

When the filtering bleb at any postoperative visit was encysted or showed signs of fibrosis leading to an increase in IOP, subconjunctival injections of MMC were administered. The subconjunctival injections consisted of 0.05 to 0.1 mL of a MMC 0.02% solution injected beneath the filtering bleb under topical anesthesia. Neodymium:YAG (Nd:YAG) capsulotomy (Microruptor V, Meridian AG) was performed when visual acuity was reduced as a result of posterior capsulopatination. Neodymium:YAG laser synechialysis was done to liberate synechia when the tube was obstructed by iris strands.

**Statistical Analysis**

Data are expressed as the mean ± SD (minimum and maximum). Results were analyzed using a 1-way analysis of variance (ANOVA) and Student t test for parametric data (IOP), Wilcoxon signed-rank test for nonparametric data (BCVA, number of medications), and Kaplan-Meier survival curves at the end of follow-up using the log-rank test. Results were considered significant when P < .05.

**RESULTS**

The Ex-PRESS R-50 device was easily implanted without perioperative complications in 35 eyes of 35 white patients with glaucoma and cataract. The mean age of the patients was 74.6 years ± 10.9 (SD) (range 49 to 90 years). Table 1 shows the patients' data.

The mean follow-up was 36.9 ± 18.2 months (range 3.7 to 37.1 months). Twenty-eight, 26, 24, and 21 patients completed the 1-, 2-, 3-, and 4-year follow-up, respectively. Three patients died, and 1 was lost to follow-up.

Mean preoperative IOP (Table 1) decreased after surgery by 21% (mean 15.3 ± 6.2 mm Hg; range 7 to

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Result</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eyes, n</td>
<td>35</td>
</tr>
<tr>
<td>Male/female, n (%)</td>
<td>12 (34.3)/23 (65.7)</td>
</tr>
<tr>
<td>Mean age (y) ± SD</td>
<td>74.6 ± 10.9</td>
</tr>
<tr>
<td>White ethnicity, n (%)</td>
<td>35 (100)</td>
</tr>
<tr>
<td>Diagnosis</td>
<td>POAG</td>
</tr>
<tr>
<td>PXFG</td>
<td>22 (62.9)</td>
</tr>
<tr>
<td>Mean follow-up (mo) ± SD</td>
<td>36.9 ± 18.2</td>
</tr>
<tr>
<td>Lost to follow-up, n (%)</td>
<td>4 (11.4)</td>
</tr>
<tr>
<td>Preoperative data</td>
<td></td>
</tr>
<tr>
<td>IOP (mm Hg)</td>
<td>19.3 ± 6.3</td>
</tr>
<tr>
<td>Range</td>
<td>10–35</td>
</tr>
<tr>
<td>Snellen BCVA</td>
<td></td>
</tr>
<tr>
<td>Mean ± SD</td>
<td>0.47 ± 0.3</td>
</tr>
<tr>
<td>Range</td>
<td>0.01–1.00</td>
</tr>
<tr>
<td>Mean medications (n) per patient ± SD</td>
<td>2.1 ± 1.1</td>
</tr>
<tr>
<td>Previous glaucoma surgery, n (%)</td>
<td>3 (8.5)</td>
</tr>
<tr>
<td>Severity of glaucoma (c/d ratio)</td>
<td></td>
</tr>
<tr>
<td>Early (0.3–0.59)</td>
<td>10 (28.6)</td>
</tr>
<tr>
<td>Moderate (0.6–0.79)</td>
<td>9 (25.7)</td>
</tr>
<tr>
<td>Severe (2.0)</td>
<td>16 (45.7)</td>
</tr>
</tbody>
</table>

BCVA = best corrected visual acuity; c/d = cup to disc; IOP = intraocular pressure; POAG = primary open-angle glaucoma; PXFG = pseudoxfoliative glaucoma
38 mm Hg) at 6 months, 22% (15.1 ± 4.6 mm Hg; 10 to 30 mm Hg) at 12 months, 29% (13.8 ± 2.8 mm Hg; 9 to 18 mm Hg) at 24 months, 24% (14.6 ± 2.9 mm Hg; 10 to 19 mm Hg) at 36 months, and 31% (13.3 ± 2.0 mm Hg; 10 to 17 mm Hg) at 48 months. The drop was significant between the preoperative and all postoperative periods (P < .005, ANOVA and Student t test). The IOP curve dropped 1 week after surgery; the drop was followed by a slight rise that stabilized at approximately 14 mm Hg without a significant variation in the IOP between 1 month and 48 months (Figure 1).

The mean preoperative BCVA (Table 1) increased to 0.74 ± 0.34 (range 0.05 to 1.00) at 48 months (P = .0003). The BCVA increase was slightly limited (<1.0) due to systemic or retinal disease not related to the initial glaucoma diagnosis. The postoperative complications had no effect on the visual outcomes. Four patients had a BCVA worse than 0.6 as a result of vascular trouble (n = 2) or age-related macular degeneration (n = 2).

The reduction in antiglaucoma medication after implantation of the Ex-PRESS R-50 device was 57% at 48 months, at which time 11 patients (35%) were receiving pharmacological treatment (P < .05); 4 patients were on 1 medication, 6 were on 2, and 1 was on 3. The number of antiglaucoma medications slightly increased over time (mean 0.4 at 6 months and 0.9 at 48 months) (Figure 2). This was probably due to a progressive loss of efficacy in the device’s filtering function, despite good IOP control.

Postoperative bleb management and fibrosis modulation were performed in 10 eyes (28.6%). The treatment included needling with or without MMC injections and Nd:YAG capsulotomy (Table 2).

Table 3 shows the postoperative complications. The minor complications resolved spontaneously in less than a month in 7 of the 10 cases. In the eye that developed a shallow anterior chamber, the chamber required inflation with an injection of an OVD. An Nd:YAG laser iridoplasty was performed in an attempt to solve the problem created by the iris-device contact. The contact did not resolve; thus, the eye required further surgical treatment. The cystic Tenon’s capsule did not resolve despite revision of the filtering bleb consisting of a tenonectomy and synechialysis.

Major complications occurred in 8 cases (Table 3). The cases of conjunctival erosion were induced by a protruding dislodged device. In the cases of complete tube obstruction, there was significant and rapid elevation in IOP over early postoperative (1 to 8 week) values. Two obstructions occurred in patients with PXFG and 2 in patients with POAG.

The device was removed in all eyes with complications, all of which required further glaucoma filtering surgery. In 1 eye with conjunctival erosion, an attempt was made to implant a new Ex-PRESS R-50 device. This was followed by a new conjunctival erosion that required surgical removal of the new device. Three eyes that required tube removal had previous bleb management with MMC injection; the reasons for

<table>
<thead>
<tr>
<th>Table 2. Postoperative interventions.</th>
<th>Eyes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intervention</td>
<td>Number (%)</td>
</tr>
<tr>
<td>Needling with MMC</td>
<td>6 (17.1)</td>
</tr>
<tr>
<td>Needling without MMC</td>
<td>4 (11.4)</td>
</tr>
<tr>
<td>Nd:YAG capsulotomy</td>
<td>5 (14.3)</td>
</tr>
</tbody>
</table>

MMC = mitomycin-C, Nd:YAG = neodymium:YAG

Figure 1. Mean IOP before surgery and at each follow-up period. The bars represent the SD.

Figure 2. Mean number of medications before surgery and at each follow-up period. The bars represent the SD.
removing these tubes were tube occlusion in 2 eyes and conjunctival erosion in 1.

At 48 months, based on the Kaplan-Meier survival curve, the cumulative qualified success rate was 53.7% and the complete success rate was 32.7% (P < .05) (Figure 3). Based on IOP and surgical criteria, 48.0% of patients had failed surgery.

### DISCUSSION

Our study of 35 eyes found a 31% reduction in IOP 48 months postoperatively with a cumulative qualified success rate of 53.7%. Based on the percentage of IOP reduction, our results compare favorably with those in other studies.10–15 Our results were obtained with a mean number of antiglaucoma medications that increased slightly over time. However, considering the qualified success rate, our results were not as favorable as those reported in the literature for other filtering procedures; that is, 60% to 100% for trabeculectomy,16–19 up to 91% to 20,21 for nonpenetrating surgery, and 45% to 80% for other glaucoma drainage devices.22–25

Two studies of the Ex-PRESS R-50 implant using the same surgical approach have been published. Traverso et al.10 implanted the device in 25 eyes and obtained a qualified success rate of 76.9%. Zarnowski et al.12 treated 16 eyes with a qualified success rate of 68%. The authors report few complications, and both groups concluded that Ex-PRESS R-50 implantation is an effective and safe procedure. Their mean follow-up (23.9 months and 6.0 months, respectively) was shorter than ours (36.9 ± 18.2 months), and this could explain the different results.

Our results do not differ significantly from those of Wamsley et al.15 in terms of the degree of IOP reduction and the high rate of complications. Most complications we encountered were also observed by Stewart et al.16 in a small case series reporting complications after Ex-PRESS implantation and by Tavolato et al.17 in a case report of a spontaneous extrusion of the Ex-PRESS device. The preoperative glaucoma history of these eyes, including the previous surgeries, as well as the type and severity of glaucoma were probably important risk factors for failure. For example, of the 10 cases that eventually ended as a failure, 2 had previous glaucoma surgery for medically uncontrolled glaucoma.

In our study, the postoperative BCVA increased by approximately 60% 18 to 24 months after surgery. This improvement was the direct benefit of cataract extraction. No patient had a postoperative BCVA lower than the preoperative BCVA.

The reduction in the mean number of medications was 57% at last follow-up. This result is encouraging; however, as the preoperative IOP was not significantly elevated, we essentially focused on lowering the number of medications rather than on IOP. The mean time before reintroducing medication was 10.5 ± 0.3 months (range 1 to 36 months) after surgery. Lachkar et al.21 report a mean time before restarting medications of 20.2 months after initial nonpenetrating deep sclerectomy and Chen et al.18 of 41 months after initial trabeculectomy. Both techniques decreased the mean number of antiglaucoma medications (by 58% and 48%, respectively) at the last postoperative follow-up. In our cases, the reintroduction of antiglaucoma medication occurred sooner; on the other hand, the quantity of drugs increased over time. This could reflect a progressive loss of efficacy in the device’s filtering function. Four of the 8 major complications in our study were due to tube obstruction that required additional treatment.

![Figure 3](https://example.com/figure3.png)

**Figure 3.** Qualified and complete cumulative success rate (P < .05).
Studies of trabeculectomy report an increased rate of cataract development after surgery, minimiz such influence by performing the surgery based solely on the patient's clinical status and interest in being involved in the study. The strength of the study lies in the long follow-up and that the same technique was used by the same surgeon for all surgeries.

CONCLUSION

In this paper, we present the long-term results of a study of combined glaucoma and cataract surgery comprising phacoemulsification and PC IOL implantation followed by the implantation of the Ex-PRESS R-50 microtube. Of the 35 eyes analyzed, 10 (32%) had satisfactory IOP control without medication. A third of the tubes had to be explanted due to major complications that required further glaucoma surgery. Reasons for this surgical failure were tube obstruction and conjunctival erosion. Modifications of the tube's geometry and the surgical technique may improve the efficiency and safety of the procedure.

REFERENCES